We assessed the reliability of prognostic biologic markers by means of immunohistochemistry on cell blocks obtained from diagnostic fine-needle cytopunctures of breast carcinomas and their lymph node metastases.
Major progress has been made in recent years in immunohistochemical detection of various markers (cell proliferation markers, hormone receptors, etc.), improving knowledge and management of breast cancer. Most work reported in the literature has been done on frozen or paraffin-embedded tumor tissues. Fine-needle cytopuncture, which is useful for pretherapeutic diagnosis of breast cancer and for monitoring its progression, often provides highly cellular material representative of the lesions (1) (2) (3) (4) (5) , which can be used for such analyses. Various studies have shown that nuclear and cytoplasmic markers can be detected individually by means of immunocytochemistry on cytopuncture smears, whereas immunohistochemical studies of cells present in paraffin miniblocks can simultaneously identify several markers on consecutive sections (6) . Whatever the technique used, however, the risk of sample contamination by ductal carcinoma in situ (DCIS) is a major problem (7) . The aim of this study was to assess the reliability of immunohistochemical detection of markers considered predictive of the prognosis and/or the response to therapy in cytoblock preparations of fine-needle cytopuncture breast cancer specimens.
We tested a series of cytoblocks from 93 patients with primary breast cancer. In 55 cases, we compared marker detection on cytoblocks and on the corresponding tissue samples to determine the reliability and difficulties of cytoblock assessment. In 38 cases, we compared cytoblocks of the mammary tumor and cytoblocks of concurrent metastatic nodes, the invasive nature of the mammary carcinoma being provided by nodal involvement.
MATERIALS AND METHODS

Populations
Cells were obtained from two groups of patients by means of diagnostic fine-needle cytopuncture, without aspiration. In the first group, consisting of 55 women with primary breast carcinoma (8 T1, 32 T2, 15 T3), we compared cytoblocks and their corresponding tissue samples (46 mastectomy specimens and 9 Trucut biopsies); node status was available in 50 cases (19 node negative and 31 node positive). The second group consisted of 38 women with primary breast carcinoma (12 T2, 7 T3, 3 T4, 5 inflammatory, and 11 initially metastatic) and concurrent node metastases (36 axillary and 2 supraclavicular).
Three cytopunctures were performed on each primary tumor or metastasis. Part of each cytopuncture specimen was smeared for cytologic diagnosis (including cytologic nuclear grading) (7) ; the material that remained in the needle was ejected into the same tube for fixation in 1 mL neutral formol for at least 1 h.
The cytoblock technique was performed with the Shandon kit according to the manufacturer's instructions (Shandon Inc., Pittsburgh, PA). We slightly modified the technique by using only one cytocentrifugation step. The button of cells formed was routinely processed and paraffin embedded. Tumor tissues were fixed in neutral formol. Immunohistochemistry was applied to 2.5-m paraffin sections of each specimen.
Immunohistochemistry
Procedure
The simultaneous procedure was applied only to cytoblocks from paired tumors and metastatic nodes (38 cases). A microwave antigen-retrieval technique was used in all cases. Sections were mounted on triethylenethiophosphoramideprecoated slides and allowed to dry at 50°C overnight. The sections were then dewaxed in xylene and hydrated through graded concentrations of alcohol. Endogenous peroxidase activity was blocked with 1% hydrogen peroxide for 15 min. Sections were then immersed in a thermoresistant plastic box containing 10 mL citrate buffer, pH 6.0, and treated in a microwave oven four times at 750 W for 5 min each. Sections were allowed to cool at room temperature for 30 min and were rinsed in Trisbuffered saline. The blocking reagent was tipped away and the primary antibodies were added for 1 h. A standard avidin-biotin-horseradish peroxidase complex was used to reveal antibody-antigen reactions. Staining was routinely developed using diaminobenzidine tetrahydrochloride followed with a light hematoxylin counterstain.
Five biologic markers were investigated. The growth fraction was assessed using MIB-1 antibodies that recognize Ki-67 antigen (Immunotech ITS, France) at 1:100 dilution. Hormone receptor expression was assessed with the antiestrogen-receptor antibody Dako-ER 1D5 at 1:30 dilution (Dako SA, Trappes, France) and the antiprogesterone-receptor antibody PR 1A6 at 1:30 dilution (Novocastra Laboratories, Newcastle, UK). P53 protein expression was detected using DO-7 antibody at 1:100 dilution (Dako). C-erb-B-2 oncoprotein expression was detected with a polyclonal antibody at 1:300 dilution (Dako).
Assessment of staining
The percentage of positive cells was scored for all of the markers. At least 100 malignant cells were considered suitable for immunohistochemistry on cytoblocks. Any nuclei with detectable staining was considered positive for Ki-67. We used a two-group classification (high and low Ki-67 when the proportions of stained nuclei were Ն20% and Ͻ20%, respectively).
Tumors were scored as positive for estrogen receptors (ER), progesterone receptors (PR), and p53 when nuclear staining was identified in at least 10% of cells and for c-erb-B-2 when definite membrane staining was identified in at least 10% of cells. Staining for these markers was classified as positive or negative (two-group classification) and also in three groups (Ͻ10%, 10 to 49%, Ն50%) to analyze strongly positive tumors (Ն50%). With these four markers, we also assessed the intensity of staining as weak (ϭ1), moderate (ϭ2), or strong (ϭ3), and a score was calculated as the percentage of positive cells multiplied by the staining intensity.
Statistical Methods
The interobserver reproducibility of the cytoblock results was assessed by two independent observers on the 55 tumors in the first group, using the coefficient to measure the degree of agreement between the two observers. The relationship between the quantitative values obtained on cytoblocks and tumor tissues was analyzed by using a nonparametric test with Spearman's rank coefficient (r).
RESULTS
Interobserver reproducibility (MB and VLD) on the cytoblocks of the first group, based on the respective cutoffs for the two-group classification, was 91% for Ki-67, 100% for ER, 93% for PR and p53, and 87% for c-erb-B-2. The agreement rate ( coefficient) was 0.81 (Ki-67), 1.00 (ER), 0.83 (PR), 0.84 (p53), and 0.74 (c-erb-B-2). The concordance rate in the three-group classifications was 96% (ER), 87% (PR), 84% (p53), and 80% (c-erb-B-2).
Comparison Between Immunoresults on Cytoblocks and on Tissue Sections (55 cases)
Thirty-seven carcinomas were purely invasive, whereas 18 also contained an in situ component. Only the invasive component was taken into account when examining tumor tissues. Comparisons of immunoresults were based on evaluation of markers done by MB on cytoblocks and VLD on tumor tissues.
Comparison of Positive-Cell Percentages Between Cytoblocks and Tissue Specimens
Median Ki-67 percentages of positive nuclei were 15% on cytoblocks (0 to 60%) and 20% (0 to 75%) on tissue specimens. The correlation coefficient between quantitative values obtained on cytoblocks and tissue specimens was 0.78. The same proportion of tumors with high Ki-67 (38%) was observed in cytoblocks and tissues. The concordance rate was 85.4% (Table 1) .
Median ER percentages of positive nuclei were 60% (0 to 100%) on cytoblocks and 70% (0 to 100%) on tissue specimens. The correlation coefficient was 0.77. In the two-group classification, the same percentage of tumors (81.8%) was ER positive on cytoblocks and tissue specimens. The concordance rate was 96.3%, compared with 85.5% in the threegroup classification (Fig. 1 ). The proportion of highly positive tumors was 69% on cytoblocks and 76.5% on tissue specimens. Two cases were clearly discrepant (negative versus highly positive Ն 50%).
Median PR percentages of positive nuclei were 20% (0 to 95%) on cytoblocks and 25% (0 to 100%) on tissue specimens. The correlation coefficient was 0.76. In the two-group classification, 37 cases were PR positive on cytoblocks (67.3%) and 39 on tissue specimens (70.9%). The concordance rate was 81.8%. In the three-group classification, the concordance rate was 70.9%. The proportion of highly positive tumors was 31% on cytoblocks and 44% on tissue specimens, with only one clearly discrepant case. Median p53 percentages of positive nuclei were 15% (0 to 100%) on cytoblocks and 8% (0 to 100%) on tissue specimens. The correlation coefficient was 0.86. In the two-group classification, 36 cases (65.4%) were p53 positive on cytoblocks, compared with 27 (49.1%) on tissue specimens. The concordance rate was 76.4%. In the three-group classification, the concordance rate was 69.1%. The proportion of highly positive tumors was 18% on cytoblocks and 20% on tissue specimens, with only one clearly discrepant case.
Median c-erb-B-2 percentages of positive cells were 15% (0 to 100%) on cytoblocks and 40% (0 to 100%) on tissue specimens. The correlation coefficient was 0.79. In the two-group classification, 31 tumors (56.4%) were c-erbB-2 positive on cytoblocks and 40 (72.7%) on tissue specimens. The concordance rate was 83.6%. In the three-group classification, the concordance rate was 67.3%. The percentage of highly positive tumors was 49% on cytoblocks and 33% on tissue specimens, with four clearly discrepant cases.
Discrepant Results
Discrepancies can be due to several causes: (1) poor fixation and/or immunostaining was probably responsible for one case of complete ER negativity on cytoblock, one case of complete PR negativity on tumor tissue, one case of complete p53 negativity on tumor tissue (despite two attempts), and two c-erb-B-2-negative cytoblocks; (2) values close to the cutoff: Ki-67 in two cases, PR in three cases, p53 in four cases, and c-erb-B-2 in one case; (3) weak staining: PR in five cases, p53 in 9 cases, and c-erb-B-2 in three cases; (4) assessment on Trucut biopsies: Ki-67 in two cases, PR in two cases, and p53 in three cases.
Discrepancies were more frequent when the tumor contained a DCIS component than when it was purely invasive (Table 2) , as follows: 3 of 18 versus 5 of 37 for Ki-67 (Fig. 2) , with large differences in 5 cases (always higher in the tumor than in the cytoblock); 1 of 18 versus 1 of 37 for ER; 5 of 18 versus 5 of 37 for PR; 5 of 18 versus 8 of 37 for p53; and 5 of 18 versus 4 of 37 for c-erb-B-2. Moreover, the correlation coefficients were better in the purely invasive subgroup than in the subgroup with DCIS.
Comparison between cytoblocks and tumor tissues based on intensity score
The quantitative values obtained by multiplying the percentage of positives cells by the staining intensity showed a fairly good correlation for ER (r ϭ .63) and PR (r ϭ .69) and a good correlation for p53 (0.86) and c-erb-B-2 (r ϭ .80) in the overall group; the correlations were stronger in the purely invasive subgroup (r ϭ .66, .72, .86, and .81, respectively).
Comparison between cytoblocks of primary tumors and cytoblocks of the corresponding concurrent node metastases
We obtained a very good correlation with all the markers between the percentage of positive cells in the primary tumors and the node metastases in the 38 cases (r ϭ .86 to .96) ( Table 3) .
Seventy-one percent of the breast tumors and 84% of the node metastases had high Ki-67 expression, and 31 of 38 cases were concordant (81.6%). Among the seven discrepant cases, only one had low Ki-67 expression in the metastatic node. Furthermore, in seven cases, there was a clear increase in the proportion of stained nuclei in the metastatic node (Ͼ10%), whereas there was a clear decrease in two cases. ER status was concordant in 36 cases (94.7%), with 28 tumors (73.7%) and 26 nodes (68.4%) being ER positive. All ER-negative tumors had ERnegative nodes, whereas two ER-positive tumors had ER-negative nodes. Moreover, two strongly ERpositive tumors (Ն50%) corresponded to a decrease in positive nuclei in nodes, and one weakly labeled ER-positive tumor (12%) had a strongly labeled node.
PR status concorded in 33 cases (86.8%). Fifteen tumors (39.5%) and 14 nodes (36.8%) were PR positive. Twenty-one PR-negative tumors had PRnegative nodes, whereas two PR-negative tumors had PR-positive nodes. Three PR-positive tumors had PR-negative nodes, including two strongly PRpositive tumors that had completely PR-negative nodes (one was a histologically heterogeneous tumor with a large DCIS component). Moreover, two tumors had nodes with far higher percentages of positive nuclei.
P53 status concorded in 35 cases (92%). Nineteen tumors (50%) and 20 nodes (52.6%) were p53 positive. Only one p53-positive tumor had a completely p53-negative node (the mammary tumor had a large DCIS component). Among the p53-negative tumors, 17 had p53-negative nodes and two had p53-positive nodes. Finally, p53 immunopositivity was lower in one node than in the corresponding tumor.
C-erb-B-2 status concorded in 35 cases (92%) (Fig. 3) . Twenty-eight tumors (73.7%) and 29 nodes (76.3%) were c-erb-B-2 positive. Only one positive tumor had a negative node, whereas two c-erb-B-2-negative tumors had positive nodes. In one case, the percentage of positive cells was higher in the node than in the tumor, whereas the reverse was true in another case.
A good correlation between the tumors and nodes was observed in regard to the percentage of positive cells multiplied by the intensity score (r ϭ .
[ER], .89 [PR], .97 [p53], .89 [c-erb-B-2]).
Comparison between the two groups of mammary cytoblocks
The second group comprised far more tumors with high Ki-67 than the first group (71 versus 38%), together with fewer ER-positive tumors (73.7 versus 82%), fewer PR-positive tumors (39.5 versus 67%), fewer p53ϭpositive tumors (50 versus 65%), slightly more strongly p53-positive tumors (32 versus 20%), more c-erb-B-2-positive tumors (74 versus 56%), and more strongly c-erb-B-2-positive tumors (58 versus 33%).
Correlations among biologic parameters in the 93 mammary cytoblocks
High Ki-67 was linked to ER and PR negativity and was more weakly linked to p53 positivity (in both the two-and three-group classifications). The three-group classification of p53 showed a very strong negative correlation with ER status and, to a lesser extent, with PR status in the three-group classification, whereas the three-group classification of c-erb-B-2 was weakly linked to PR status (two-and three-group classifications). Finally, ER and PR status (two-and three-group classifications) were very strongly correlated with each other; 73.1% of tumors were ER positive and PR positive (Table 4) .
Correlations among biologic parameters, cytologic nuclear grade, and node status (Table 5)
High Ki-67, ER negativity, and p53 positivity correlated with high nuclear grade (Grade 2). High Ki-67, PR negativity, and c-erb-B-2 positivity correlated with node invasion. The other parameters were not significantly linked to node status.
DISCUSSION
Fine-needle cytopuncture of breast carcinoma often provides highly cellular material that is rep- resentative of the tumors. These samples can be used not only for cytologic diagnosis but also to obtain information on the prognosis and likely response to therapy.
Recent years have seen major technological developments aimed at gleaning the maximum amount of information from this type of sample, through immunocytohistochemistry, image analysis and flow cytometry, and now cytogenetics and molecular biology (1) (2) (3) (4) (5) (6) (7) (8) .
The possibility of including cells in miniblocks and thereby obtaining multiple sections has been the subject of several reports, but it was Pinder et al. (6) who first studied the value of this method for analyzing multiple prognostic markers by means of immunohistochemistry in breast cancer. Pinder et al.'s study focused on samples obtained by fineneedle aspiration (FNA) of resected tumors, whereas we worked exclusively on samples obtained before therapy by in vivo cytopuncture, when cellularity of the sample was obvious. Consequently, we did not seek to determine what proportion of breast cancers would yield useable cytoblocks. We used Pinder et al.'s technique with slight modifications. To evaluate the reliability of the method and to identify possible sources of error in the assessment of the different immunomarkers on cytoblocks of the primary breast tumor, we com- pared our breast cytoblock findings with those obtained on the corresponding tissues specimens or on the concomitant node metastases when sampled. Overall, cytoblock immunostaining was of good quality and free of artifacts such as excessive background. However, cytoplasmic positivity for hormone receptors hindered interpretation in one case with ER and in six cases with PR on the cytoblock of the primary tumor; similar positivity was always found on the corresponding tumor tissue sample or on the cytoblock of the metastatic node. These cases of cytoplasmic positivity seemed to be linked to the nature of the tumor tissue.
The good interobserver reproducibility observed here reflects the quality of the immunostaining and the simplicity of the interpretation; however, c-erb-B-2 membrane staining was a little more difficult to interpret than nuclear staining, leading to less good reproducibility (87% versus 91 to 100%).
Depending on the marker, a correlation of 76 to 96% was observed between the cytoblocks and the corresponding tumor tissues in the two-group classifications (negative versus positive). Makris et al. (3) obtained a similar level of agreement for ER, PR, and p53 by means of immunocytochemistry on multiple slides of FNA material after cytocentrifugation. Our correlations were a little less satisfactory in the three-group classification, which individualizes strong positivity. When we used a score taking intensity into account, a very good correlation was obtained with p53 and c-erb-B-2 (r ϭ .86 and .80).
In addition to technical problems (which cannot always be overcome, especially on small samples) and more conventional problems such as intra-and interobserver variability, the discrepancies we observed were linked to weak staining and values close to the cutoff; in addition, small samples (cytoblocks and microbiopsies) may not be representative of heterogeneous breast tumors. The impact of tumor heterogeneity, especially when an in situ component is combined with the invasive component (nearly one third of our cases), emerged clearly in this series, as the percentage concordance and correlation coefficients were always better in the purely invasive tumor subgroup than in the subgroup of tumors with a DCIS component.
It is difficult to compare our results with previously published data, because the antibodies, cutoffs, immunostaining assessment (taking into account or not staining intensity), the number of subgroups, and also the study populations vary widely from one report to another.
Positivity cutoffs for Ki-67 range from 10 to 25%, and the percentage of tumors with high Ki-67 range from 26 to 85%, according to the authors (2, 9 -13). According to Clahsen et al. (10) and on the basis of two personal studies (unpublished data), one comparing the corresponding values of Ki-67 and SPF, the other studying the prognostic value of SPF in a series of breast carcinoma, we have chosen a cutoff of 20. With this cutoff, we found that 38% tumors had high Ki-67 on both cytoblocks and tissue sections.
With p53, the reported cutoffs range from 1 to 75% (2, 9, 10, (13) (14) (15) (16) (17) (18) (19) and the proportion of positive tumors from 14 to 60%. Pinder et al., applying a cutoff of 5 to cytoblocks, obtained 46% of positive tumors. Six studies with a cutoff of 10 (15), showed a proportion of positive tumors ranging from 16 to 51%. Our histologic results for p53 are within this range, whereas the value obtained on cytoblock was higher (65%), despite the absence of values between 5 and 10%. However, our percentage of strongly positive tumors (20%) is comparable to that reported elsewhere (2, 13, 20) . The c-erb-B-2 cutoff is usually 1 or 5. An extensive review of the literature (21) showed that 10 to 34% of breast cancers had HER-2/neu gene amplification or c-erb-B-2 protein overexpression when examined immunohistochemically. Pinder et al., using a cutoff of 1, found 38% of positive tumors on cytoblocks. Our percentage of positive tumors was higher on cytoblocks (56%) and even more so on tumor tissues (73%), possibly owing to the sensitivity of the antibodies at the dilution used or to the composition of our population (56% of nodepositive tumors). However, Solomides et al. (5) recently found percentages similar to ours in their study of cytology specimens. Finally, the percentage of highly positive tumors in our study (33%) is higher than that reported by Rozan et al. (13) but close to that of Berger et al. (22) .
Comparisons of hormone receptors are easier, because they are better studied and coded, with well-established comparisons with biologic assays (23, 24) and clinical features (25) (26) (27) . Although, once again, there is no international consensus on cutoff values, several authors recommend a value of 10% positive nuclei (1, (27) (28) (29) , without taking labeling intensity into account. The percentages of ERpositive tumors (82% on cytoblocks and tissues) and PR-positive tumors (67% on cytoblocks and 71% on tissues) are in keeping with those generally observed in the literature, whether the percentages of positive nuclei are considered alone (1) or combined with staining intensity (3, 4, 30, 31) , if one considers the median age of our patients (60 years).
An excellent correlation was observed in the second group between cytoblock immunostaining of the breast tumor and of the corresponding metastatic node. This type of comparison is rare. Bhargava et al. (32) , in their series of 24 invasive primary breast cancers with node metastases, observed full concordance on histologic sections between p53 immunopositivity of the primary tumor and metastatic node, and Barnes et al. (33) obtained similar results for c-erb-B-2. These data suggest that the metastatic cell population is very similar to the invasive breast tumor cell population, in keeping with studies based on flow cytometry (34, 35) and molecular biology (36, 37) . Certain conflicting results in our series can be linked to the presence of a DCIS component (e.g., explaining why Ki-67 labeling was more often higher in the metastases than in the corresponding primary tumors [84% versus 71%]) or to genetic alterations occurring in some cases during the metastatic process, as shown by means of comparative genomic hybridization (38) .
Overexpression of proteins related to proliferative activity and c-erb-B-2 oncoprotein, which was more frequent in the primary tumors of the second than of the first group, and the opposite trend in hormone receptors is probably linked to the presence of several very aggressive tumors (inflammatory and initially metastatic) in our series.
Correlations between the various biologic parameters in the mammary cytoblocks are in keeping with those frequently described by other authors. As reported by others (1, 39), Ki-67 was significantly linked to p53, and these two markers correlated negatively with ER and PR status (3, 39, 40) . As in all previous studies, ER and PR were very significantly linked; 73% of tumors were ER positive and PR positive, a proportion close to that obtained by Sauer et al. (4) by immunocytochemistry on FNA slides. Finally, c-erb-B-2 was not linked to any of the other markers, except for a negative correlation with PR also found by other authors (39, 41) .
As expected, the markers of cell proliferation Ki-67 and p53 were significantly linked to our cytologic nuclear grade, whereas ER correlated negatively with nuclear grade.
In our study, node invasion correlated with high Ki-67 expression, PR negativity, and c-erb-B-2 positivity. Ki-67 labeling was high in 62% of nodepositive tumors and in only 21% of node-negative tumors, the latter result being close to that obtained by Dettmar et al. (42) . The proportion of ERpositive tumors ranged from 89 to 74% and that of PR-positive tumors from 79 to 48% according to node status, but, contrary to Bozetti et al. (1) , we found that only PR was significantly linked to node status.
A correlation between c-erb-B-2 overexpression and node status was found here, as by Berger et al. (22) , but not by other authors (39, 41) . This correlation was found also for highly positive tumors (Ն50%), which were more numerous in the nodepositive (54%) than in the node-negative (16%) population. Once again, the proportion of nodepositive tumors that were strongly positive was far higher than that found by Thor et al. (43) . Although p53 did not seem to be significantly linked to node status in our study, highly p53-positive tumors were more numerous in the node-positive (29%) that in the node-negative (16%) population.
These results suggest that despite the imperfections inherent to this technique, the need to obtain highly cellular samples, and the problem of tumor heterogeneity, cytoblocks can be a useful alternative for marker detection, especially for inoperable carcinoma or when neoadjuvant treatment is planned. Moreover, the coherence of the results obtained here demonstrates that useful information can be obtained on metastatic cell populations not only for diagnostic purposes (samples no longer being contaminated by a DCIS component) but also in the research setting.
Finally, aggressive tumors with a poor prognosis, especially those with node involvement, clearly overexpressed proteins related to proliferative activity and oncoproteins.
